An Observer-blind Study to Assess the Safety, Reactogenicity and Immunogenicity of Different Formulations of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women
Phase of Trial: Phase II
Latest Information Update: 19 Aug 2017
At a glance
- Drugs GSK 3003891A (Primary) ; DTaP vaccine
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms RSV F-020
- Sponsors GlaxoSmithKline
- 28 Jul 2016 Status changed from active, no longer recruiting to completed.
- 15 Jul 2016 The trial was completed in Germany.
- 01 Jun 2016 The trial was completed in Czech Republic.